Therapy Areas
All Sessions
Resectable NSCLC
Metastatic NSCLC
SCLC
Biomarkers & Diagnostics
DRUG CLASSES
Targeted Therapies
Immuno-therapies
Antibody-Drug Conjugates
View Sessions
Dec
18
2025
METASTATIC NSCLC, SCLC
2025 Approvals & Highlights
1 h 49 min
Sep
26
2025
METASTATIC NSCLC
LATEST OPTIONS FOR NON-ONCOGENE ADDICTED METASTATIC NSCLC IN FRONTLINE AND BEYOND
32 min
Sep
26
2025
IMMUNOTHERAPIES
THE ROLE OF IO ADDED TO CHEMORADIATION IN UNRESECTABLE STAGE III NSCLC
28 min
Sep
26
2025
SPONSORED INTERVIEW
Latest Advances in Frontline EGFR+ NSCLC
14 min
Sep
26
2025
INDUSTRY SYMPOSIUM
UNLOCKING NEW POTENTIALS IN EGFR-MUTANT NSCLC
30 min
Sep
26
2025
ADCs
THE ADC REVOLUTION IN LUNG CANCER: NEW TARGETS, NEW OPPORTUNITIES
27 min
Sep
26
2025
TARGETED THERAPIES
DEBATE: WHICH IS THE BETTER CHOICE IN EGFR+ METASTATIC NSCLC?
31 min
Sep
26
2025
TARGETED THERAPIES
ACTIONABLE GENOMIC ALTERATIONS – INCLUDING HER2 AND MET
26 min
Sep
26
2025
TARGETED THERAPIES
TARGETING EGFR AND ALK IN NSCLC
26 min
Sep
26
2025
METASTATIC NSCLC
Open Discussion on Patient Cases
22 min
Jul
10
2025
TARGETED THERAPIES
Targeted Therapies in NSCLC
1h 30 min
Jun
25
2025
IMMUNOTHERAPIES
Immunotherapies in NSCLC
1h 47 min
Oct
05
2024
ASTRAZENECA & DAIICHI-SANKYO
Best Practices in Managing Adverse Events with ADCs in NSCLC
18 min
Oct
04
2024
METASTATIC NSCLC, RESECTABLE NSCLC
Patient Cases & Open Questions
32 min
Oct
04
2024
METASTATIC NSCLC
DEBATE: Balancing Efficacy, Toxicity, and Patient-Centered Care For IO Duration in NSCLC
33 min